News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

The Evolving Treatment Landscape in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EP. 1: DLBCL: Circumstances for Deviating Away From R-CHOP

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

EP. 2: DLBCL: Treatment Considerations for Challenging Populations

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

EP. 3: DLBCL: Treating Patients Following Relapse on Frontline Therapy

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

EP. 4: R/R DLBCL: Second-Line Treatment Options

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

EP. 5: Tafasitamab Combined With Lenalidomide in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

EP. 6: R/R DLBCL: Treating With Tafasitamab-Lenalidomide

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

EP. 7: Novel Therapies for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

EP. 8: CAR T-Cell Therapy for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

EP. 9: CAR-T Treatment Options for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

EP. 10: Treating R/R DLBCL With CAR-T: Current Barriers

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

EP. 11: Understanding the CAR-T Process: Collection Through Infusion

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

EP. 12: CAR T for R/R DLBCL: Safety/Tolerability

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

EP. 13: CAR T for R/R DLBCL: Improving Access and Utilization

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

EP. 14: R/R DLBCL: Transplants in the Era of CAR-T

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

EP. 15: Bridging Therapy in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

EP. 16: Treating Primary Refractory DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

EP. 17: R/R DLBCL: Novel Therapies in the Pipeline

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

EP. 18: R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

EP. 19: Evolving Therapies in R/R DLBCL: Concluding Remarks

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL